SELLAS Life Sciences Group, Inc. Common Stock (SLS)
SELLAS Life Sciences Group, Inc. (SLS) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company's portfolio includes treatments designed to enhance the immune system's ability to recognize and destroy cancer cells, with an emphasis on innovative approaches to immuno-oncology. SELLAS aims to address unmet medical needs through its research-driven pipeline and strategic collaborations.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 5, 2011 | $0.24 | 2011-03-24 | 2011-03-28 |
| December 20, 2010 | $0.42 | 2010-12-09 | 2010-12-13 |
| September 22, 2010 | $0.15 | 2010-09-09 | 2010-09-13 |
| June 21, 2010 | $0.09 | 2010-06-10 | 2010-06-14 |
| March 29, 2010 | $0.09 | 2010-03-18 | 2010-03-22 |
Dividends Summary
- SELLAS Life Sciences Group, Inc. Common Stock has issued 11 dividend payments over the past 3 years
- The most recent dividend was paid 5282 days ago, on April 5, 2011
- The highest dividend payed out to investors during this period was $0.4375 per share
- The average dividend paid during this period was $0.23 per share.
Company News
Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.
SELLAS presented preclinical data showing that its CDK9 inhibitor SLS009 demonstrated potent anti-proliferative activity in ASXL1 mutant colorectal cancer cell lines, suggesting its potential as a targeted therapy for this patient population.
Galena Biopharma (SLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The following new investment ideas were made by analysts who have NO OTHER Buy/Strong Buy recommendations in the past 3 months. Check out the picks for April 2024.